Emergent's anthrax vax granted fast track status; Novartis' Menveo broader use app accepted;

Vaccine Research

Investigators have found a small, but life-threatening risk associated with GlaxoSmithKline's Rotarix, a rotavirus vaccine. The vax, which prevents the most common cause of dehydration and severe diarrhea in children, caused intussusception in 1 in 51,000 to 1 in 68,000 inoculated babies. The CDC emphasized that the risk does not outweigh the benefits of being vaccinated. Report

Vaccine Market

The FDA has granted Emergent BioSolutions fast track status for its investigational anthrax vaccine, NuThrax. The new vaccine combines Emergent's BioThrax with CPG 7909, an immunostimulatory compound, and is currently in Phase Ib testing. Emergent release

Novartis' application for broader use of its meningitis vaccine, Menveo, has been accepted by the FDA. If approved, the vaccine could be used with infants as young as two months old. It's currently approved in the U.S. for two to 55 year olds. Item

The CDC has held its first of four public meetings around the U.S. to determine whether to recommend bacterial meningitis shots for infants. Currently, the group only recommends the vax for 11 to 18 year olds, but the FDA has approved a jab for children 9 months and older. Article

Denmark and an unidentified European NATO nation have purchased doses of Bavarian Nordic's smallpox vaccine, Imvamune. The company believes these orders, while smaller than the contract it has with the U.S., could pave the way towards "a long-term cooperation on building up a modern biopreparedness." News

About 95% of parents confirmed their children are receiving their recommended vaccines, according to a CDC study. Only 2% of parents said they would not innoculate their children at all. Item

And Finally... Precious Reynolds, an 8-year-old from Willow Creek, CA, has become the third person in the U.S. to survive rabies without a rabies vaccine. She contracted the illness after being scratched by an infected stray cat. Story

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.